https://doi.org/10.55788/f1deafce
The CRC-PIPAC-II study, presented by Dr Vincent van de Vlasakker (Catharina Hospital, the Netherlands), included 20 patients undergoing a combined total of 52 bi-directional treatment cycles [1]. With an impressive 75% of patients successfully completing the trial treatment, the PIPAC approach demonstrated robust feasibility. "The dropout rate was low, with only 1 patient discontinuing due to toxicity," Dr van de Vlasakker commented. "This suggests that our approach is not only feasible but also safe."
In terms of efficacy, the trial reported encouraging results. The median progression-free survival was 10 months, while the median overall survival was 17.5 months. "These numbers are promising, especially when compared with the typical overall survival of 12 months observed with systemic therapy alone," the study lead noted.
However, the trial's results were not without complications. The impact on patient’s quality of life was mixed. Adverse events included abdominal pain, peripheral neuropathy, nausea, vomiting, and fatigue. However, an improvement in emotional functioning was also observed. "Despite the safety of the treatment, it is crucial not to overlook its significant impact on patients' lives," Dr van de Vlasakker cautioned.
The overall conclusion from this trial was that the PIPAC technique represents an innovative leap in intra-peritoneal therapies, demonstrating that a high-dose, localised treatment strategy could improve outcomes for patients with advanced peritoneal metastases. However, the complexity and mixed impact on quality of life suggests that this approach should be reserved for carefully selected patients, while more research is needed to further refine and assess this technique.
- van de Vlasakker V, et al. Outcomes of first-line palliative systemic therapy alternated with oxaliplatin-based pressurized intraperitoneal aerosol chemotherapy in patients with unresectable colorectal peritoneal metastases in a multicenter, single-arm, phase II trial. Lecture 727, DDW 2023, 6–9 May, Chicago, IL, USA.
Copyright ©2023 Medicom Medical Publishers
Posted on
Previous Article
« Effectiveness of B/F/TAF treatment in HIV/HBV co-infection Next Article
Colorectal cancer: Aspirin and NSAIDs could reduce the risk of early-onset adenomas »
« Effectiveness of B/F/TAF treatment in HIV/HBV co-infection Next Article
Colorectal cancer: Aspirin and NSAIDs could reduce the risk of early-onset adenomas »
Table of Contents: DDW 2023
Featured articles
EVOLVE Expansion study: vedolizumab and ustekinumab as first-line biologic treatments for Crohn’s disease
PIPAC technique shows promise for unresectable colorectal peritoneal metastases
Upper GI Disorders: Hot Topics
Dupilumab improves eosinophilic oesophagitis outcomes, regardless of history of oesophageal dilation
Inflammatory Bowel Disease: Novel Developments
EVOLVE Expansion study: vedolizumab and ustekinumab as first-line biologic treatments for Crohn’s disease
Environmental and dietary factors can amplify paediatric IBD risk
Ulcerative colitis: bowel urgency remission associated with improvement in fatigue
Crohn’s disease: Upadacitinib improves endoscopic outcomes in participants with or without previous biologic failure
Microbiota in GI Diseases
Durability of SER-109 clinical response in patients with recurrent Clostridioides difficile infection
IBS management: the complex role of dietary fibres
Daily and seasonal fluctuations in the gut microbiome
Spotlight on Colorectal Cancer
Colorectal cancer: Aspirin and NSAIDs could reduce the risk of early-onset adenomas
PIPAC technique shows promise for unresectable colorectal peritoneal metastases
What is New in Hepatology?
Terlipressin shows promise for participants with hepatorenal syndrome and concomitant alcoholic hepatitis
Related Articles
November 20, 2020
Even mild NAFLD associated with higher mortality
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy